Amber Implants Announces Successful One-Year Follow-Up Data in First-in-Human Clinical of VCFix® Spinal System
- One-year follow-up data from first-in-human trial shows significant improvements in key clinical performance outcomes
- This data supports a strong safety profile for the VCFix® Spinal System for the treatment of vertebral compression fractures
The Hague, The Netherlands, 3 June 2025 – Amber Implants, an innovative medical technology company developing next-generation implants for spinal injuries, today announces the completion of the one-year follow-up for all patients enrolled in its first-in-human clinical trial of the VCFix® Spinal System. This milestone marks a significant step in demonstrating the safety of VCFix® for the treatment of vertebral compression fractures.
